Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.

Curtis M, Kenny HA, Ashcroft B, Mukherjee A, Johnson A, Zhang Y, Helou Y, Batlle R, Liu X, Gutierrez N, Gao X, Yamada SD, Lastra R, Montag A, Ahsan N, Locasale JW, Salomon AR, Nebreda AR, Lengyel E.

Cell Metab. 2018 Aug 28. pii: S1550-4131(18)30508-4. doi: 10.1016/j.cmet.2018.08.007. [Epub ahead of print]

PMID:
30174305
2.

m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer.

Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, Tienda SM, Chryplewicz A, Zhu AC, Yang Y, Huang JT, Chen SM, Xu ZG, Leng XH, Yu XC, Cao J, Zhang Z, Liu J, Lengyel E, He C.

Nat Cell Biol. 2018 Sep;20(9):1074-1083. doi: 10.1038/s41556-018-0174-4. Epub 2018 Aug 27.

PMID:
30154548
3.

The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis.

Curtis M, Mukherjee A, Lengyel E.

Trends Cancer. 2018 Aug;4(8):517-519. doi: 10.1016/j.trecan.2018.06.002. Epub 2018 Jun 22.

PMID:
30064659
4.

Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.

Matsuda T, Leisegang M, Park JH, Ren L, Kato T, Ikeda Y, Harada M, Kiyotani K, Lengyel E, Fleming GF, Nakamura Y.

Clin Cancer Res. 2018 May 2. doi: 10.1158/1078-0432.CCR-18-0142. [Epub ahead of print]

PMID:
29720506
5.

Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors.

Lengyel E, Makowski L, DiGiovanni J, Kolonin MG.

Trends Cancer. 2018 May;4(5):374-384. doi: 10.1016/j.trecan.2018.03.004. Epub 2018 Apr 5. Review.

PMID:
29709261
6.

Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.

Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, Yamada SD, Abumrad NA, Lengyel E.

Oncogene. 2018 Apr;37(17):2285-2301. doi: 10.1038/s41388-017-0093-z. Epub 2018 Feb 5.

7.

An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells.

Li G, Montgomery JE, Eckert MA, Chang JW, Tienda SM, Lengyel E, Moellering RE.

Nat Commun. 2017 Nov 24;8(1):1775. doi: 10.1038/s41467-017-01854-0.

8.

Who are the long-term survivors of high grade serous ovarian cancer?

Hoppenot C, Eckert MA, Tienda SM, Lengyel E.

Gynecol Oncol. 2018 Jan;148(1):204-212. doi: 10.1016/j.ygyno.2017.10.032. Epub 2017 Nov 8. Review.

PMID:
29128106
9.

High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.

Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF.

Gynecol Oncol. 2017 Jul;146(1):153-160. doi: 10.1016/j.ygyno.2017.04.012. Epub 2017 Apr 26.

10.

A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth.

Lal-Nag M, McGee L, Guha R, Lengyel E, Kenny HA, Ferrer M.

SLAS Discov. 2017 Jun;22(5):494-506. doi: 10.1177/2472555216687082. Epub 2017 Jan 31.

11.

Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.

Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL.

Cancer Prev Res (Phila). 2017 Apr;10(4):255-266. doi: 10.1158/1940-6207.CAPR-16-0281. Epub 2017 Mar 6.

12.

Unsaturated Fatty Acids Maintain Cancer Cell Stemness.

Mukherjee A, Kenny HA, Lengyel E.

Cell Stem Cell. 2017 Mar 2;20(3):291-292. doi: 10.1016/j.stem.2017.02.008.

13.

Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity.

Sundaram KM, Zhang Y, Mitra AK, Kouadio JK, Gwin K, Kossiakoff AA, Roman BB, Lengyel E, Piccirilli JA.

Cancer Res. 2017 Apr 1;77(7):1684-1696. doi: 10.1158/0008-5472.CAN-16-1454. Epub 2017 Feb 15.

14.

Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube.

Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel E.

Cancer Discov. 2016 Dec;6(12):1342-1351. Epub 2016 Oct 7.

15.

Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells.

Nakamura K, Sawada K, Kinose Y, Yoshimura A, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Morishige KI, Kurachi H, Lengyel E, Kimura T.

Mol Cancer Res. 2017 Jan;15(1):78-92. doi: 10.1158/1541-7786.MCR-16-0191. Epub 2016 Oct 6.

16.

Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers.

Liu X, Romero IL, Litchfield LM, Lengyel E, Locasale JW.

Cell Metab. 2016 Nov 8;24(5):728-739. doi: 10.1016/j.cmet.2016.09.005. Epub 2016 Oct 13.

17.

Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.

Coscia F, Watters KM, Curtis M, Eckert MA, Chiang CY, Tyanova S, Montag A, Lastra RR, Lengyel E, Mann M.

Nat Commun. 2016 Aug 26;7:12645. doi: 10.1038/ncomms12645.

18.

Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.

Zhang Y, Sriraman SK, Kenny HA, Luther E, Torchilin V, Lengyel E.

Mol Cancer Ther. 2016 Oct;15(10):2282-2293. Epub 2016 Jul 27.

19.

A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies.

Fehniger J, Thomas S, Lengyel E, Liao C, Tenney M, Oto A, Yamada SD.

Gynecol Oncol. 2016 Jul;142(1):169-175. doi: 10.1016/j.ygyno.2016.04.018. Epub 2016 Apr 28.

PMID:
27103176
20.

Erratum: Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.

Kenny HA, Lal-Nag M, White EA, Shen M, Chiang CY, Mitra AK, Zhang Y, Curtis M, Schryver EM, Bettis S, Jadhav A, Boxer MB, Li Z, Ferrer M, Lengyel E.

Nat Commun. 2016 Feb 3;7:10649. doi: 10.1038/ncomms10649. No abstract available.

21.

Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity.

Peters PN, Schryver EM, Lengyel E, Kenny H.

J Vis Exp. 2015 Dec 31;(106):e53541. doi: 10.3791/53541.

22.

Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.

Nature. 2015 Nov 19;527(7578):398. doi: 10.1038/nature15716. Epub 2015 Oct 21. No abstract available.

PMID:
26503049
23.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.

Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Review.

24.

Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer.

Litchfield LM, Mukherjee A, Eckert MA, Johnson A, Mills KA, Pan S, Shridhar V, Lengyel E, Romero IL.

Oncotarget. 2015 Sep 15;6(27):23548-60.

25.

Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.

Stringer-Reasor EM, Baker GM, Skor MN, Kocherginsky M, Lengyel E, Fleming GF, Conzen SD.

Gynecol Oncol. 2015 Sep;138(3):656-62. doi: 10.1016/j.ygyno.2015.06.033. Epub 2015 Jun 24.

26.

Discharge of thoracic patients on portable digital suction: Is it cost-effective?

Southey D, Pullinger D, Loggos S, Kumari N, Lengyel E, Morgan I, Yiu P, Nandi J, Luckraz H.

Asian Cardiovasc Thorac Ann. 2015 Sep;23(7):832-8. doi: 10.1177/0218492315589671. Epub 2015 Jun 11.

PMID:
26071448
27.

Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.

Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410. Erratum in: Nature. 2015 Nov 19;527(7578):398.

PMID:
26017449
28.

MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment.

Kohlhapp FJ, Mitra AK, Lengyel E, Peter ME.

Oncogene. 2015 Nov 26;34(48):5857-68. doi: 10.1038/onc.2015.89. Epub 2015 Apr 13. Review.

29.

The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.

Kinose Y, Sawada K, Nakamura K, Sawada I, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Takahashi K, Kurachi H, Lengyel E, Kimura T.

Oncotarget. 2015 May 10;6(13):11342-56.

30.

Patterns and utility of routine surveillance in high grade endometrial cancer.

Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD.

Gynecol Oncol. 2015 Jun;137(3):485-9. doi: 10.1016/j.ygyno.2015.03.047. Epub 2015 Mar 30.

31.

Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis.

Mitra AK, Chiang CY, Tiwari P, Tomar S, Watters KM, Peter ME, Lengyel E.

Oncogene. 2015 Nov 26;34(48):5923-32. doi: 10.1038/onc.2015.43. Epub 2015 Mar 23.

32.

Molecular pathways: trafficking of metabolic resources in the tumor microenvironment.

Romero IL, Mukherjee A, Kenny HA, Litchfield LM, Lengyel E.

Clin Cancer Res. 2015 Feb 15;21(4):680-6. doi: 10.1158/1078-0432.CCR-14-2198. Review.

33.

Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.

Kenny HA, Lal-Nag M, White EA, Shen M, Chiang CY, Mitra AK, Zhang Y, Curtis M, Schryver EM, Bettis S, Jadhav A, Boxer MB, Li Z, Ferrer M, Lengyel E.

Nat Commun. 2015 Feb 5;6:6220. doi: 10.1038/ncomms7220. Erratum in: Nat Commun. 2016;7:10649.

34.

Old drug, new trick: repurposing metformin for gynecologic cancers?

Febbraro T, Lengyel E, Romero IL.

Gynecol Oncol. 2014 Dec;135(3):614-21. doi: 10.1016/j.ygyno.2014.10.011. Epub 2014 Oct 23. Review.

35.

Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.

Lengyel E, Litchfield LM, Mitra AK, Nieman KM, Mukherjee A, Zhang Y, Johnson A, Bradaric M, Lee W, Romero IL.

Am J Obstet Gynecol. 2015 Apr;212(4):479.e1-479.e10. doi: 10.1016/j.ajog.2014.10.026. Epub 2014 Oct 19.

36.

Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.

Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, Montag A, Wroblewski K, Yamada SD, Mazar AP, Bowtell D, Lengyel E.

J Clin Invest. 2014 Oct;124(10):4614-28. doi: 10.1172/JCI74778. Epub 2014 Sep 9.

37.

WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer.

King ML, Lindberg ME, Stodden GR, Okuda H, Ebers SD, Johnson A, Montag A, Lengyel E, MacLean Ii JA, Hayashi K.

Oncogene. 2015 Jun;34(26):3452-62. doi: 10.1038/onc.2014.277. Epub 2014 Sep 1.

38.

Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis.

Habis M, Wroblewski K, Bradaric M, Ismail N, Yamada SD, Litchfield L, Lengyel E, Romero IL.

PLoS One. 2014 Aug 13;9(8):e104521. doi: 10.1371/journal.pone.0104521. eCollection 2014.

39.

Three-dimensional modeling of ovarian cancer.

White EA, Kenny HA, Lengyel E.

Adv Drug Deliv Rev. 2014 Dec 15;79-80:184-92. doi: 10.1016/j.addr.2014.07.003. Epub 2014 Jul 14. Review.

40.

Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype.

Ko SY, Ladanyi A, Lengyel E, Naora H.

Am J Pathol. 2014 Jan;184(1):271-81. doi: 10.1016/j.ajpath.2013.09.017.

41.

Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy.

Zhang Y, Kenny HA, Swindell EP, Mitra AK, Hankins PL, Ahn RW, Gwin K, Mazar AP, O'Halloran TV, Lengyel E.

Mol Cancer Ther. 2013 Dec;12(12):2628-39. doi: 10.1158/1535-7163.MCT-13-0204. Epub 2013 Sep 23.

42.

Epithelial ovarian cancer experimental models.

Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS.

Oncogene. 2014 Jul 10;33(28):3619-33. doi: 10.1038/onc.2013.321. Epub 2013 Aug 12. Review.

43.

Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting.

Landen CN Jr, Lengyel E.

Gynecol Oncol. 2013 Jul;130(1):6-8. No abstract available.

PMID:
23926600
44.

Adipose tissue and adipocytes support tumorigenesis and metastasis.

Nieman KM, Romero IL, Van Houten B, Lengyel E.

Biochim Biophys Acta. 2013 Oct;1831(10):1533-41. doi: 10.1016/j.bbalip.2013.02.010. Epub 2013 Mar 14. Review.

45.

miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin α5 expression.

Ohyagi-Hara C, Sawada K, Kamiura S, Tomita Y, Isobe A, Hashimoto K, Kinose Y, Mabuchi S, Hisamatsu T, Takahashi T, Kumasawa K, Nagata S, Morishige K, Lengyel E, Kurachi H, Kimura T.

Am J Pathol. 2013 May;182(5):1876-89. doi: 10.1016/j.ajpath.2013.01.039. Epub 2013 Mar 15.

PMID:
23499550
46.

Ferromagnetic quantum critical point in the heavy-fermion metal YbNi4(P(1-x)As(x))2.

Steppke A, Küchler R, Lausberg S, Lengyel E, Steinke L, Borth R, Lühmann T, Krellner C, Nicklas M, Geibel C, Steglich F, Brando M.

Science. 2013 Feb 22;339(6122):933-6. doi: 10.1126/science.1230583.

47.

Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma.

Lengyel E, Fleming S, McEwen KA, Montag A, Temkin SM.

Gynecol Oncol. 2013 Apr;129(1):120-3. doi: 10.1016/j.ygyno.2012.12.006. Epub 2012 Dec 10.

48.

MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer.

Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, Lengyel E.

Cancer Discov. 2012 Dec;2(12):1100-8. doi: 10.1158/2159-8290.CD-12-0206. Epub 2012 Nov 21.

49.

HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts.

Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, Naora H.

J Clin Invest. 2012 Oct;122(10):3603-17. doi: 10.1172/JCI62229. Epub 2012 Sep 4.

50.

Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure.

Tergas AI, Buell-Gutbrod R, Gwin K, Kocherginsky M, Temkin SM, Fefferman A, Lengyel E, Yamada SD.

Gynecol Oncol. 2012 Nov;127(2):316-20. doi: 10.1016/j.ygyno.2012.07.105. Epub 2012 Jul 24.

PMID:
22835717

Supplemental Content

Loading ...
Support Center